| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/15/2004 | US20040009163 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2004 | DE10229070A1 Phenylderivate 5 Phenyl derivatives 5 |
| 01/15/2004 | DE10227938A1 Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung A pharmaceutical preparation, processes for their preparation and their use |
| 01/15/2004 | CA2767092A1 Novel compounds, pharmaceutical compositions containing same and methods of use for same |
| 01/15/2004 | CA2493906A1 Therapeutics for diabetes mellitus |
| 01/15/2004 | CA2492122A1 Novel tricyclic spiropiperidines or spiropyrrolidines |
| 01/15/2004 | CA2492121A1 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 01/15/2004 | CA2492037A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 01/15/2004 | CA2492035A1 N-hydroxyamide derivatives possessing antibacterial activity |
| 01/15/2004 | CA2492033A1 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| 01/15/2004 | CA2491998A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 01/15/2004 | CA2491994A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | CA2491848A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | CA2491710A1 Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491573A1 Methods of treating microbial infections in humans and animals |
| 01/15/2004 | CA2491479A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491464A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | CA2491455A1 Novel use of imidazotriazinones |
| 01/15/2004 | CA2491451A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2491286A1 Methods of screening compounds for grk6 modulating activity |
| 01/15/2004 | CA2491132A1 Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/15/2004 | CA2491127A1 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490494A1 Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds |
| 01/15/2004 | CA2490145A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2490142A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | CA2489860A1 Use of an antibody against s100a8 or s100a9 as chemotactic factor inhibitor for modulating inflammatory reactions |
| 01/15/2004 | CA2489562A1 Mitotic kinesin binding site |
| 01/15/2004 | CA2489396A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | CA2489251A1 Quinazoline derivatives |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/15/2004 | CA2485379A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 01/15/2004 | CA2460051A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |
| 01/14/2004 | EP1380593A1 Soluble rage protein |
| 01/14/2004 | EP1380581A1 Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases |
| 01/14/2004 | EP1380579A1 Novel physiologically active substances |
| 01/14/2004 | EP1380577A1 Thiazoline acid derivatives |
| 01/14/2004 | EP1380576A1 Novel 1h-indazole compound |
| 01/14/2004 | EP1380571A1 Compounds useful for treating allergic and inflammatory diseases |
| 01/14/2004 | EP1380307A1 Tissue fibrosis inhibitors |
| 01/14/2004 | EP1380305A1 Photodynamic therapy for the enhancement of vascular permeability |
| 01/14/2004 | EP1380297A1 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclo-hepta[1,2-b]pyridine oral compositions |
| 01/14/2004 | EP1380296A1 Hsp inductor |
| 01/14/2004 | EP1379994A2 Extracorporeal blood processing information management system |
| 01/14/2004 | EP1379869A1 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal |
| 01/14/2004 | EP1379689A2 Oligonucleotide conjugates |
| 01/14/2004 | EP1379688A2 Polymorphisms in the human cmoat gene and uses thereof |
| 01/14/2004 | EP1379679A2 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 01/14/2004 | EP1379672A2 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 01/14/2004 | EP1379665A2 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| 01/14/2004 | EP1379656A2 G-protein coupled receptor molecules and uses thereof |
| 01/14/2004 | EP1379654A2 Intracellular signaling molecules |
| 01/14/2004 | EP1379652A2 Human nucleic acid molecules and polypeptides encoding a human ion channel expressed in spinal cord and brain |
| 01/14/2004 | EP1379649A2 Calcium binding proteins |
| 01/14/2004 | EP1379637A2 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379555A2 Modified interferon alpha with reduced immunogenicity |
| 01/14/2004 | EP1379547A2 Pro-drug and use thereof as a medicament |
| 01/14/2004 | EP1379542A2 Treatment of tumours |
| 01/14/2004 | EP1379535A2 Expression vectors able to elicit improved immune response and methods of using same |
| 01/14/2004 | EP1379528A1 Pyrazolopyrimidines as therapeutic agents |
| 01/14/2004 | EP1379524A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379522A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I |
| 01/14/2004 | EP1379519A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379517A2 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 01/14/2004 | EP1379516A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 01/14/2004 | EP1379514A2 5-membered heterocycles, preparation and application thereof as medicaments |
| 01/14/2004 | EP1379513A1 Prodrugs of cox-2 inhibitors |
| 01/14/2004 | EP1379511A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| 01/14/2004 | EP1379510A1 Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers |
| 01/14/2004 | EP1379508A2 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379505A2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| 01/14/2004 | EP1379503A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379501A1 Indolinones, substituted in position 6, and their use as kinase inhibitors |
| 01/14/2004 | EP1379498A1 Sulphones which modulate the action of gamma secretase |
| 01/14/2004 | EP1379496A1 Sulphones which modulate the action of gamma secretase |
| 01/14/2004 | EP1379495A2 Ligands of the alpha-v-beta 6 integrin |
| 01/14/2004 | EP1379494A1 Fused bicyclic or tricyclic amino acids |
| 01/14/2004 | EP1379493A2 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| 01/14/2004 | EP1379492A1 Inhibitor of monoamine uptake |
| 01/14/2004 | EP1379282A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders |
| 01/14/2004 | EP1379276A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/14/2004 | EP1379272A2 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies |
| 01/14/2004 | EP1379271A1 Method for treating von willebrand's disease |
| 01/14/2004 | EP1379267A1 The use of the protein uk114 for the treatment and the prevention of chronic active hepatitis |
| 01/14/2004 | EP1379262A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 01/14/2004 | EP1379258A1 Low salt forms of polyallylamine |
| 01/14/2004 | EP1379257A2 Prodrugs of anticancer agents employing substituted aromatic acids |
| 01/14/2004 | EP1379255A2 Substituted tetracycline compounds as antifungal agents |
| 01/14/2004 | EP1379254A1 Use of bile acid or bile salt fatty acid conjugates |
| 01/14/2004 | EP1379250A2 A method of treating cancer |